ReviewBiomedicines2022
The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Faecal microbiota transplantation for treating acute lower gastrointestinal graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.The Cochrane database of systematic reviews · 2026Pooled it
- Trial
- Fecal Microbiota Transplantation and Microbiota-Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions.Clinical pharmacology and therapeutics · 2026Review
- The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies.Translational oncology · 2026Review
- Review
- Review
- "The microbiome in graft-versus-host disease: a tale of two ecosystems".Journal of translational medicine · 2025Review
- Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease.Annals of hematology · 2025Review
- Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with Defibrotide.Journal of experimental pharmacology · 2025Article
- Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.Frontiers in medicine · 2025Review
- Impact of gut colonization by antibiotic-resistant bacteria on the outcomes of autologous stem cell transplantation in multiple myeloma.Scientific reports · 2024Article
- Gut microbiota plays pivotal roles in benign and malignant hematopoiesis.Blood science (Baltimore, Md.) · 2024Review
- Gut microbiota, microbiota-derived metabolites, and graft-versus-host disease.Cancer medicine · 2024Review
- Longitudinal dynamics of gut microbiota in the pathogenesis of acute graft-versus-host disease.Cancer medicine · 2023Article
- The Role of Fecal Microbiota Transplantation in the Allogeneic Stem Cell Transplant Setting.Microorganisms · 2023Review
- Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients.Life science alliance · 2023Article
- Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases.World journal of clinical cases · 2022Review
- Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study.Frontiers in microbiology · 2022Review
- Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of allogeneic hematopoietic stem cell transplantations conducted worldwide is constantly rising. Together with that, the absolute number of complications after the procedure is increasing, with graft-versus-host disease (GvHD) being one of the most common. The standard treatment is steroid administration, but only 40-60% of patients will respond to the therapy and some others will be steroid-dependent. There is still no consensus regarding the best second-line option, but fecal microbiota transplantation (FMT) has shown encouraging preliminary and first clinically relevant results in recent years and seems to offer great hope for patients. The reason for treatment of steroid-resistant acute GvHD using this method derives from studies showing the significant immunomodulatory role played by the intestinal microbiota in the pathogenesis of GvHD. Depletion of commensal microbes is accountable for aggravation of the disease and is associated with decreased overall survival. In this review, we present the pathogenesis of GvHD, with special focus on the special role of the gut microbiota and its crosstalk with immune cells. Moreover, we show the results of studies and case reports to date regarding the use of FMT in the treatment of steroid-resistant acute GvHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.